The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
24-hydroxycholesterol affects the metabolism of and results in increased activity of APP protein; 24-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 24-hydroxycholesterol results in increased metabolism of APP protein
24-hydroxycholesterol results in increased expression of CCL2 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]
24-hydroxycholesterol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]
CYP46A1 gene SNP affects the abundance of 24-hydroxycholesterol CYP46A1 protein results in increased chemical synthesis of 24-hydroxycholesterol CYP46A1 protein results in increased metabolism of 24-hydroxycholesterol
24-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
24-hydroxycholesterol results in increased expression of ITGB1 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]
24-hydroxycholesterol results in increased expression of MMP9 mRNA Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of MMP9 mRNA]
Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]
24-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]
Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] 27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein [Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA
27-hydroxycholesterol results in increased expression of ACTA2 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]
27-hydroxycholesterol results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]
27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 27-hydroxycholesterol results in increased expression of APP protein alternative form 27-hydroxycholesterol results in decreased secretion of APP protein alternative form
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]
27-hydroxycholesterol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein] 27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein
27-hydroxycholesterol results in decreased activity of CES1 protein 27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin]
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein] 27-hydroxycholesterol results in increased activity of CTNNB1 protein
27-hydroxycholesterol results in increased expression of CXCL12 mRNA fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]
CYP27A1 protein results in increased abundance of 27-hydroxycholesterol [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol
CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein] 27-hydroxycholesterol results in increased degradation of ESR1 protein ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] ESR1 protein affects the susceptibility to 27-hydroxycholesterol
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] ESR2 protein affects the susceptibility to 27-hydroxycholesterol
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]
27-hydroxycholesterol results in increased expression of HIF1A protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]
27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein] 27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]
27-hydroxycholesterol results in increased secretion of IL6 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]
27-hydroxycholesterol results in decreased activity of LDLR protein 27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein
LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]
27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein]
27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]
27-hydroxycholesterol results in increased expression of MMP9 mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA]
27-hydroxycholesterol results in increased expression of MYC protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]
27-hydroxycholesterol results in decreased expression of NOS3 mRNA 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased activity of NR5A1 protein 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]
27-hydroxycholesterol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]
27-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] STAR protein results in increased abundance of 27-hydroxycholesterol 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] 27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein] Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]
27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]
27-hydroxycholesterol results in increased expression of TLR4 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein] 27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein
27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]
[NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA
25-hydroxycholesterol results in increased expression of ABCA1 mRNA [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol co-treated with alitretinoin] results in increased expression of ABCA1 protein; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA] [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA
25-hydroxycholesterol results in increased expression of ACTA2 mRNA 15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]
[25-hydroxycholesterol co-treated with alitretinoin] results in decreased expression of ADIPOR1 mRNA 25-hydroxycholesterol results in decreased expression of ADIPOR1 mRNA
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]
25-hydroxycholesterol results in increased activity of CASP8 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]
25-hydroxycholesterol results in increased activity of CASP9 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 25-hydroxycholesterol
CYP7B1 protein results in increased metabolism of 25-hydroxycholesterol CYP7B1 gene mutant form results in increased abundance of 25-hydroxycholesterol
25-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
25-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
25-hydroxycholesterol inhibits the reaction [beta-hydroxy simvastatin acid results in increased expression of FADS1 mRNA] 25-hydroxycholesterol results in decreased expression of FADS1 mRNA
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Brefeldin A inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Dactinomycin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Genistein inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [25-hydroxycholesterol co-treated with Mevalonic Acid] results in increased ubiquitination of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein] 25-hydroxycholesterol results in decreased expression of HMGCR protein 25-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 25-hydroxycholesterol results in decreased activity of HMGCR protein 25-hydroxycholesterol results in decreased expression of HMGCR mRNA; 25-hydroxycholesterol results in decreased expression of HMGCR protein
25-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] 25-hydroxycholesterol results in increased secretion of IL1B protein 25-hydroxycholesterol results in increased expression of IL1B mRNA
25-hydroxycholesterol results in increased secretion of IL6 protein 25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] 25-hydroxycholesterol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
25-hydroxycholesterol results in decreased expression of LDLR mRNA; 25-hydroxycholesterol results in decreased expression of LDLR protein 25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of LDLR mRNA]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]
25-hydroxycholesterol results in increased activity of NR1H3 protein [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein]
25-hydroxycholesterol results in increased activity of NR5A1 protein 25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]
[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]
25-hydroxycholesterol binds to RORC protein bisphenol A analog inhibits the reaction [25-hydroxycholesterol binds to RORC protein]; T0901317 inhibits the reaction [25-hydroxycholesterol binds to RORC protein]
25-hydroxycholesterol results in increased expression of SREBF1 protein [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein
25-hydroxycholesterol results in decreased activity of SREBF2 protein 25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of SREBF2 protein modified form]; [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein]
SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein] SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 25-hydroxycholesterol]
27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] [Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]
27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 27-hydroxycholesterol results in increased expression of APP protein alternative form 27-hydroxycholesterol results in decreased secretion of APP protein alternative form
27-hydroxycholesterol results in increased expression of CCL2 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]
27-hydroxycholesterol results in increased expression of CCN5 mRNA Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]
27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]
27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin] 27-hydroxycholesterol results in decreased activity of CES1 protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein] 27-hydroxycholesterol results in increased activity of CTNNB1 protein
27-hydroxycholesterol results in increased expression of CXCL12 mRNA fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]
CYP27A1 protein results in increased abundance of 27-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol
CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein] ESR1 protein affects the susceptibility to 27-hydroxycholesterol ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] 27-hydroxycholesterol results in increased degradation of ESR1 protein
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] ESR2 protein affects the susceptibility to 27-hydroxycholesterol ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased phosphorylation of GSK3B protein 27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]
27-hydroxycholesterol results in increased expression of HIF1A protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein] 27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein 27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]
27-hydroxycholesterol results in increased secretion of IL6 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]
27-hydroxycholesterol results in decreased activity of LDLR protein 27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein
LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]
27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]
27-hydroxycholesterol results in increased expression of MYC protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased activity of NR5A1 protein 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]
27-hydroxycholesterol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]
27-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] 27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein STAR protein results in increased abundance of 27-hydroxycholesterol 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
27-hydroxycholesterol results in increased phosphorylation of STAT3 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein] Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
27-hydroxycholesterol results in increased expression of TFF1 mRNA 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]
27-hydroxycholesterol results in increased secretion of VEGFA protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]
27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]
CYP27A1 protein results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid
3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]; 3-hydroxy-5-cholestenoic acid binds to and results in increased activity of NR1H3 protein
[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol CYP3A4 protein results in increased chemical synthesis of cholest-5-ene-3,4-diol
EPHX1 protein results in increased metabolism of cholesterol alpha-oxide disparlure promotes the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]; Lanosterol analog inhibits the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]
cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]
cholesterol alpha-oxide results in increased phosphorylation of MTOR protein RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein]
7-ketocholesterol results in decreased expression of ABCD1 mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]
7-ketocholesterol results in decreased expression of ABCD3 mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG5 mRNA 7-ketocholesterol results in decreased expression of ABCG5 mRNA
[7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG8 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG8 mRNA
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ACAT1 mRNA
7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA] 7-ketocholesterol binds to AHR protein
7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein]
7-ketocholesterol results in increased expression of BAX protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]
Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]
7-ketocholesterol results in decreased expression of BID protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]
7-ketocholesterol results in increased activity of CASP3 protein 7-ketocholesterol results in increased cleavage of CASP3 protein alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]; argan oil inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein] 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein] 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]
7-ketocholesterol results in increased activity of CASP7 protein Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP7 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]
7-ketocholesterol results in increased expression of CCL2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL2 protein]
7-ketocholesterol results in increased expression of CCL4 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL4 protein]
7-ketocholesterol results in increased expression of CSF2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF2 protein]
7-ketocholesterol results in increased expression of CSF3 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF3 protein]
7-ketocholesterol affects the localization of CYBB protein Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein]
7-ketocholesterol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] 7-ketocholesterol inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] 7-ketocholesterol results in decreased expression of CYP1A1 protein
7-ketocholesterol results in decreased activity of HMGCR protein 7-ketocholesterol results in increased expression of HMGCR mRNA [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of HMGCR mRNA
7-ketocholesterol results in decreased expression of IL10 mRNA resveratrol promotes the reaction [7-ketocholesterol results in increased expression of IL10 protein]
7-ketocholesterol results in increased expression of IL1B protein Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]
7-ketocholesterol results in increased expression of IL6 protein 7-ketocholesterol results in decreased degradation of and results in increased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA
7-ketocholesterol results in increased expression of MAP1LC3B protein CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein]
U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein] RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]
7-ketocholesterol results in increased phosphorylation of MAPK3 protein RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein] U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]
7-ketocholesterol results in increased expression of MMP2 mRNA 7-ketocholesterol results in increased expression of MMP2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP2 protein]
7-ketocholesterol results in increased expression of MMP9 mRNA 7-ketocholesterol results in increased expression of MMP9 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP9 protein]
7-ketocholesterol results in increased phosphorylation of MTOR protein RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]
7-ketocholesterol results in increased expression of NFKB1 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein] resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]
7-ketocholesterol results in increased phosphorylation of NFKBIA protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of NFKBIA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]
7-ketocholesterol results in increased cleavage of PARP1 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]
7-ketocholesterol inhibits the reaction [Methylcholanthrene results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [Quercetin results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [resveratrol results in increased expression of PON1 mRNA]
7-ketocholesterol results in decreased expression of PPARA mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]
7-ketocholesterol affects the localization of PYCARD protein Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]
7-ketocholesterol results in increased expression of RELA protein 7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein] resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of RELA protein]
SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]
7-ketocholesterol results in increased expression of TP53 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]
7-ketocholesterol results in increased expression of VEGFA protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of VEGFA protein]
[AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; AKR1D1 gene mutant form inhibits the reaction [AKR1D1 protein results in increased metabolism of 7 alpha-hydroxy-4-cholesten-3-one]
APP protein results in increased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol cholest-5-en-3 beta,7 alpha-diol results in decreased secretion of APP protein
alpha-Tocopherol inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL2 mRNA]
cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL3 protein cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL3 mRNA
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL4 mRNA cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL4 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]
cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]
cholest-5-en-3 beta,7 alpha-diol results in decreased activity of LPL protein cholest-5-en-3 beta,7 alpha-diol results in decreased expression of LPL mRNA
cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA]
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGS2 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of TLR4 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]
DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol [BM 15766 results in decreased activity of DHCR7 protein] which results in increased abundance of 7-dehydrocholesterol DHCR7 results in increased reduction of 7-dehydrocholesterol Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol]
cholestane-3,5,6-triol results in increased expression of BCL2 mRNA Sodium Selenite inhibits the reaction [cholestane-3,5,6-triol results in increased expression of BCL2 mRNA]
cholestane-3,5,6-triol results in decreased activity of CAT protein alpha-Tocopherol inhibits the reaction [cholestane-3,5,6-triol results in decreased activity of CAT protein]; beta Carotene inhibits the reaction [cholestane-3,5,6-triol results in decreased activity of CAT protein]; Butylated Hydroxytoluene inhibits the reaction [cholestane-3,5,6-triol results in decreased activity of CAT protein]
cholestane-3,5,6-triol affects the localization of CYCS protein Butylated Hydroxytoluene inhibits the reaction [cholestane-3,5,6-triol affects the localization of CYCS protein]
ABCA1 protein results in increased export of Cholesterol cholesterol cotreated with 25-hydroxycholesterol decreases expression of abca1 mrna and protein in rat hepatoma cells; and increases expression of abca1 mRNA in rat fibroblasts 1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; 1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Resveratrol results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; glycolaldehyde inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Glyoxal inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]] [[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA; Cholesterol inhibits the reaction [bisphenol A results in decreased expression of ABCA1 mRNA] ABCA1 protein affects the export of Cholesterol [[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [[Plant Preparations co-treated with Cholesterol, Dietary] results in increased expression of ABCA1 mRNA] which results in increased secretion of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; [Cholesterol co-treated with Dietary Fats] results in increased expression of ABCA1 mRNA; [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCA1 mRNA
[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol] [resveratrol results in increased expression of ABCG1 protein] which results in increased secretion of Cholesterol
Cholesterol results in increased activity of ABCG2 protein Sulfasalazine promotes the reaction [Cholesterol results in increased activity of ABCG2 protein]
ABCG5 protein affects the export of Cholesterol [Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG5 mRNA] which results in decreased secretion of Cholesterol Cholesterol results in increased expression of ABCG5 mRNA Cholesterol results in decreased expression of ABCG5 mRNA [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG5 mRNA; Cholates promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]
ABCG8 protein results in increased secretion of Cholesterol [Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG8 mRNA] which results in decreased secretion of Cholesterol Cholesterol results in increased expression of ABCG8 mRNA Cholesterol results in decreased expression of ABCG8 mRNA [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG8 mRNA; Cholates promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol] ABCG8 protein affects the export of Cholesterol
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACACA mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACACA mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA]
[Copper co-treated with Cholesterol] results in increased activity of ACHE protein; Clioquinol inhibits the reaction [[Copper co-treated with Cholesterol] results in increased activity of ACHE protein]
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein]
Cholesterol inhibits the reaction [irbesartan results in increased expression of AGT protein] [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGT mRNA; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Losartan inhibits the reaction [AGT protein affects the abundance of Cholesterol] Cholesterol results in increased expression of AGT protein
[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA; [Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein; [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGTR2 mRNA; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA]; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein]
[beta-Naphthoflavone results in increased activity of AHR protein] which results in decreased chemical synthesis of and results in decreased secretion of Cholesterol
Cholesterol inhibits the reaction [irbesartan results in increased expression of AKT1 protein] [Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein] Cholesterol results in increased expression of and results in increased phosphorylation of AKT1 protein
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein; [lard co-treated with Cholesterol] results in increased expression of ALB protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]
1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [Acrolein affects the metabolism of APOA1 protein] which results in decreased secretion of Cholesterol; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Acrolein inhibits the reaction [APOA1 protein affects the transport of Cholesterol]; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Fingolimod Hydrochloride promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; isosilybin A promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; Resveratrol inhibits the reaction [APOA1 protein results in increased export of Cholesterol] [Ethanol co-treated with APOA1 protein] results in decreased abundance of Cholesterol APOA1 affects the transport of Cholesterol Cholesterol results in decreased expression of APOA1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; [Glutathione co-treated with Quercetin] promotes the reaction [APOA1 protein results in increased export of Cholesterol]; [T0901317 co-treated with APOA1 protein] results in increased secretion of Cholesterol; Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Quercetin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]
Cholesterol results in increased expression of APOB protein Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein]
APOE protein affects the susceptibility to Cholesterol Cholesterol affects the localization of APOE protein Cholesterol promotes the reaction [APOE protein binds to CAV1 protein] APOE gene mutant form results in increased abundance of Cholesterol APOE protein results in increased export of Cholesterol 24-diamino-5-phenylthiazole inhibits the reaction [T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]]; [[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol; [APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol; APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]; APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]; N-butyloxycarbonyl-methionyl-aspartyl-glycyl-cysteinyl-glutamyl-leucine inhibits the reaction [[[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]
Cholesterol results in increased expression of AREG mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]
Cholesterol analog results in decreased expression of BAX mRNA Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]
Cholesterol analog results in decreased expression of BCL2 mRNA Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]
[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein]
Cholesterol analog results in increased expression of CASP1 mRNA Cholesterol results in increased cleavage of CASP1 protein Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein]
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; [Copper co-treated with Cholesterol] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein modified form]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol results in increased activity of CASP3 protein] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein Cholesterol results in increased cleavage of CASP3 protein Cholesterol analog results in increased expression of CASP3 mRNA Cholesterol analog results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of CASP8 protein] Cholesterol analog results in increased expression of CASP8 mRNA; Cholesterol results in increased expression of CASP8 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]
[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein] Cholesterol results in increased expression of CAT protein
CAV1 protein results in increased transport of Cholesterol CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein] Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL2 mRNA; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of CCL2 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 protein] [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein] Cholesterol results in increased expression of CCL2 mRNA; Cholesterol results in increased expression of CCL2 protein
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; [Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]; Losartan promotes the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]
[[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol
CES1 protein results in increased metabolism of Cholesterol CES1 protein results in increased abundance of Cholesterol Cholesterol results in increased expression of CES1 mRNA
[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein; [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; Cholesterol binds to and results in increased activity of CLEC4E protein; CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA] CLEC4E protein results in increased susceptibility to Cholesterol
Cholesterol results in increased expression of CLEC5A mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]
[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein]
Cholesterol results in increased expression of CSF1 mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]
[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein] Cholesterol analog affects the localization of CYBB protein
CYP27A1 protein results in decreased chemical synthesis of Cholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; CYP27A1 protein results in increased hydroxylation of and results in decreased abundance of Cholesterol [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of CYP27A1 mRNA CYP27A1 protein results in increased secretion of Cholesterol
[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol; Cholesterol promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol
CYP7A1 protein affects the metabolism of Cholesterol CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]; CYP7A1 mRNA inhibits the reaction [Tretinoin results in increased abundance of Cholesterol] CYP7A1 protein results in increased metabolism of Cholesterol Cholesterol results in increased expression of CYP7A1 mRNA turmeric extract promotes the reaction [Cholesterol results in increased expression of CYP7A1 mRNA]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein]
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of DGAT1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of DGAT1 mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]
DHCR24 protein affects the abundance of Cholesterol [DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol
DHCR7 mutant form results in decreased abundance of Cholesterol Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] DHCR7 mutant form affects the susceptibility to Cholesterol
Cholesterol affects the expression of DIO1 mRNA Cholesterol results in decreased expression of DIO1 mRNA Cholesterol results in decreased activity of DIO1 protein
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the abundance of Reactive Oxygen Species; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the abundance of Reactive Oxygen Species]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased susceptibility to Silver Compounds; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]; EGF protein affects the susceptibility to [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds]; EGF protein inhibits the reaction [[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species]
Cholesterol results in increased phosphorylation of EIF4EBP1 protein CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]
[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein; [Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]
Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of FADD protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of FADD protein]
Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA] [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAS mRNA Cholesterol analog results in increased expression of FAS mRNA 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]
[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]
Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]; Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA] [1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of FGF7 protein
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of GPAM mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of GPAM mRNA
Cholesterol results in increased phosphorylation of GSK3B protein [Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein] CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]
Cholesterol results in increased phosphorylation of H2AX protein bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]]
Cholesterol results in decreased activity of HMGCR protein cholesterol decreases expression of Hmgcr mRNA in liver [Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; [turmeric extract co-treated with Cholesterol] results in decreased expression of HMGCR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Selenium promotes the reaction [Cholesterol results in decreased expression of HMGCR mRNA] [25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol; [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [artemisic acid results in decreased expression of HMGCR protein] which results in decreased chemical synthesis of Cholesterol; [Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]
[Cholesterol co-treated with Particulate Matter] results in increased expression of HMOX1 mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of HMOX1 mRNA]
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]
[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein]
[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]
[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein] Cholesterol results in increased expression of IL1B protein Cholesterol analog results in increased expression of IL1B protein [Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL1B protein; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein]; bisphenol A promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; Quercetin inhibits the reaction [Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein] [Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; [Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA] Cholesterol results in increased expression of IL1B mRNA
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL6 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 protein] [Cholesterol co-treated with Particulate Matter] results in increased expression of IL6 mRNA; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein] Cholesterol results in increased expression of IL6 mRNA; Cholesterol results in increased expression of IL6 protein
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]
LCAT protein results in increased acylation of Cholesterol [Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]
LDLR protein results in increased uptake of Cholesterol LDLR protein affects the abundance of Cholesterol LDLR gene mutant form results in increased susceptibility to Cholesterol (+)-JQ1 compound inhibits the reaction [LDLR gene mutant form results in increased susceptibility to Cholesterol]; [LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol; [Tobacco Smoke Pollution promotes the reaction [LDLR protein affects the susceptibility to Dietary Fats]] which results in increased abundance of Cholesterol; argatroban inhibits the reaction [[LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]; Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol] Cholesterol results in decreased expression of LDLR mRNA [Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; [turmeric extract co-treated with Cholesterol] results in increased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Selenium inhibits the reaction [Cholesterol results in decreased activity of LDLR protein]; Selenium inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA] [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]
Cholesterol results in increased expression of LPL mRNA [Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]
[Capsaicin results in decreased expression of LRP1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in decreased expression of LRP1 protein] which results in increased secretion of Cholesterol
Cholesterol results in increased expression of MAP1LC3B protein modified form Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of MAP1LC3B protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA]
[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form]
Cholesterol results in increased stability of MARCHF6 protein Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [Glycerol results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [MARCHF6 protein results in increased ubiquitination of and results in increased degradation of MARCHF6 protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT2 mRNA Cholesterol results in increased expression of MT2 protein
[Cholesterol co-treated with Resveratrol] inhibits the reaction [bisphenol A results in decreased expression of NBN protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]
Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 protein] Cholesterol results in increased expression of NCF1 mRNA; Cholesterol results in increased expression of NCF1 protein
Cholesterol results in increased expression of NFE2L2 mRNA alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]
Cholesterol results in increased expression of NFKB1 protein Cholesterol inhibits the reaction [irbesartan results in increased expression of NFKB1 protein]
Cholesterol inhibits the reaction [irbesartan results in increased phosphorylation of NFKBIB protein] Cholesterol results in increased phosphorylation of NFKBIB protein
[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein] Cholesterol analog affects the localization of NLRP3 protein [Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]
NPC1 protein results in increased secretion of Cholesterol NPC1 affects the localization of Cholesterol NPC1 protein affects the abundance of Cholesterol Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Cholesterol]
Cholesterol results in increased expression of NQO1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NQO1 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]
[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol; NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol] Cholesterol results in increased activity of NR1H2 protein
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Cholesterol co-treated with Ozone] results in increased lipidation of NR1H3 protein Cholesterol increases expression of NR1H3 mRNA in epithelial cells cholesterol decreases expression of LXR mRNA in liver NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]
[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol] cholesterol decreases expression of Nr1h4 mRNA in liver NR1H4 protein results in increased export of Cholesterol
NR1I3 protein affects the metabolism of Cholesterol [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased abundance of Cholesterol Cholesterol metabolite binds to NR1I3 protein
[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein]
Cholesterol deficiency results in decreased activity of P2RX1 protein jasplakinolide inhibits the reaction [Cholesterol deficiency results in decreased activity of P2RX1 protein]
bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]]
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of PKLR mRNA
PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]
PON1 protein results in decreased chemical synthesis of Cholesterol [Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] PON1 protein results in increased export of Cholesterol Cholesterol results in decreased activity of PON1 protein
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]] Cholesterol results in decreased expression of PPARA mRNA [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [resveratrol results in decreased abundance of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [[troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol; Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol] [Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA; [lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA]; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]
Cholesterol analog results in increased expression of PYCARD mRNA Cholesterol analog affects the localization of PYCARD protein [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein] [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PYCARD mRNA; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]
Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein] Cholesterol results in increased expression of RAC1 mRNA; Cholesterol results in increased expression of RAC1 protein Cholesterol inhibits the reaction [irbesartan results in increased expression of RAC1 mRNA]
Cholesterol inhibits the reaction [irbesartan results in increased expression of RELA protein] [Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein] [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]] Cholesterol results in increased expression of RELA protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein] Cholesterol inhibits the reaction [Nicotine results in increased phosphorylation of RPS6 protein]
Trehalose inhibits the reaction [Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of RPS6KB1 protein]]; Trehalose inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6KB1 protein]
Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]
[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA] SCARB1 protein affects the transport of Cholesterol
Cholesterol results in increased expression of SCD1 mRNA [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SCD1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of SCD1 mRNA Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA]
[6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA] [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein; Resveratrol inhibits the reaction [[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein]
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]
[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein]
SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]
SORT1 protein results in decreased abundance of Cholesterol Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]
Cholesterol results in increased degradation of SQLE protein Cholesterol inhibits the reaction [Hydroxymethylglutaryl-CoA Reductase Inhibitors results in decreased degradation of SQLE protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]
Cholesterol results in increased expression of SQSTM1 protein Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of SQSTM1 protein]
SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SREBF1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of SREBF1 mRNA [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; [[Troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; betadex inhibits the reaction [SREBF2 protein results in increased abundance of Cholesterol]; SREBF2 promotes the reaction [bisphenol A results in increased import of Cholesterol]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased abundance of Cholesterol] [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein]
STAR protein affects the transport of Cholesterol STAR protein results in increased transport of Cholesterol STAR protein results in increased export of Cholesterol [[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR protein] 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]
Cholesterol results in increased expression of TGFB1 mRNA [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of TNF protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF protein] [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]] Cholesterol analog results in increased expression of TNF mRNA [Cholesterol co-treated with Particulate Matter] results in increased expression of TNF mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein] Cholesterol results in increased expression of TNF mRNA; Cholesterol results in increased expression of TNF protein
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA
Cholesterol results in increased expression of VCAM1 mRNA; Cholesterol results in increased expression of VCAM1 protein [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein]
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate LIPG gene mutant form results in increased abundance of cholesteryl linolenate
LIPG gene mutant form affects the abundance of cholesteryl myristate [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate LIPG gene mutant form results in increased abundance of cholesteryl oleate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate LIPG gene mutant form results in increased abundance of cholesteryl palmitate
DHCR24 protein results in increased metabolism of Desmosterol [DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Desmosterol analog; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of Desmosterol analog
High-density lipoprotein inhibits the reaction [cholesterol increases expression of ITGAM protein on monocytes and granulocytes] High-density lipoprotein inhibits the reaction [PMA increases expression of ITGAM protein on monocytes]
ABCA1 protein promotes the reaction [anacetrapib results in increased export of Cholesterol, HDL]; ABCA1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL] ABCA1 gene polymorphism affects the abundance of Cholesterol, HDL
ABCG1 protein promotes the reaction [anacetrapib results in increased export of Cholesterol, HDL]; ABCG1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein]; [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein; Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein
PON1 protein binds to [APOA1 protein binds to Cholesterol, HDL] APOA1 protein results in increased abundance of Cholesterol, HDL APOA1 protein inhibits the reaction [Lipopolysaccharides results in decreased abundance of Cholesterol, HDL] Fatty Acids, Unsaturated affects the reaction [APOA1 promoter SNP affects the abundance of Cholesterol, HDL]
APOE gene polymorphism affects the abundance of Cholesterol, HDL APOE gene polymorphism results in increased abundance of Cholesterol, HDL [[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol, HDL; [APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, HDL analog; [APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Cholesterol, HDL; N-butyloxycarbonyl-methionyl-aspartyl-glycyl-cysteinyl-glutamyl-leucine inhibits the reaction [[[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol, HDL]
[Niacin results in decreased expression of and results in decreased activity of CERT1 protein] which results in increased abundance of Cholesterol, HDL
Dietary Fats affects the reaction [LIPC promoter SNP affects the abundance of Cholesterol, HDL] LIPC gene polymorphism affects the abundance of Cholesterol, HDL; LIPC promoter SNP affects the abundance of Cholesterol, HDL
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Cholesterol, HDL results in increased phosphorylation of and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Cholesterol, HDL results in increased phosphorylation of and results in increased activity of MAPK3 protein
[Arsenic results in increased expression of and results in increased secretion of MMP9 protein] which results in decreased abundance of Cholesterol, HDL
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein Cholesterol, HDL results in increased expression of NOS3 protein
Cholesterol, HDL results in increased activity of PON1 protein PON1 protein binds to [APOA1 protein binds to Cholesterol, HDL] PON1 gene polymorphism affects the abundance of Cholesterol, HDL; PON1 polymorphism affects the abundance of Cholesterol, HDL PON1 gene polymorphism affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]
Niacin promotes the reaction [SCARB1 protein results in increased export of Cholesterol, HDL] Fenofibrate inhibits the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]; SDZ HDL 376 analog inhibits the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]; SDZ HDL 376 inhibits the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]
TNF gene polymorphism affects the abundance of Cholesterol, HDL Cholesterol, HDL inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Carbon Tetrachloride] results in increased expression of TNF protein]
Albiflorin inhibits the reaction [oxidized LDL increases phosphorylation of MAP3K7 protein in umbilical vein endothelial cells] Oxidized LDL increases phosphorylation of MAP3K7 protein in umbilical vein endothelial cells
Oxidized LDL decreases expression of Nr1h3 mRNA and protein in vascular smooth muscle cells Oxidized LDL increases expression of NR1H3 protein in macrophages
Oxidized low-density lipoprotein increases expression of PHACTR1 mRNA in umbilical vein endothelial cells Oxidized low density lipoprotein increases expression of short length PHACTR1 mRNA in macrophages Oxidized low density lipoprotein decreases expression of intermediate length PHACTR1 mRNA in macrophages
browse the term
